Curanex Pharmaceuticals Inc
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
CURX$6.20-0.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
UNAUDITED STATEMENTS OF CASH FLOWS
| For the six Months Ended June 30, | |||
|---|---|---|---|
| 2026 · 2025 | |||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net loss for the period | $(6,441,198) | $(197,929) | |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||
| Amortization of right-of-use assets | 71,677 | 29,663 | |
| Stock-based Compensation Expense | 9,792 | - | |
| Interest expense | - | (4,447) | |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses | 4,399,844 | (5,110) | |
| Lease liabilities | (70,340) | (29,048) | |
| Accounts payable | (2,272) | (4,731) | |
| Interest payable | - | 4,447 | |
| Accrued expenses | (2,174) | (4,553) | |
| Other current assets | - | (228,321) | |
| NET CASH USED IN OPERATING ACTIVITIES | (2,034,671) | (440,029) | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Loan from shareholders | - | 400,000 | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | - | 400,000 | |
| NET DECREASE IN CASH | (2,034,671) | (40,029) | |
| Cash at beginning of period | 4,973,134 | 148,891 | |
| CASH AT END OF PERIOD | $2,938,463 | $108,862 | |
| Supplemental schedule of cash flow information: | |||
| Non-cash investing & financing activities: | |||
| Recognition of right-of-use asset in exchange for lease liability | $ | - | $105,501 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.